BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 2003518)

  • 1. Bone mineral density in postmenopausal women treated with L-thyroxine.
    Adlin EV; Maurer AH; Marks AD; Channick BJ
    Am J Med; 1991 Mar; 90(3):360-6. PubMed ID: 2003518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.
    Greenspan SL; Greenspan FS; Resnick NM; Block JE; Friedlander AL; Genant HK
    Am J Med; 1991 Jul; 91(1):5-14. PubMed ID: 1858829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
    Ongphiphadhanakul B; Puavilai G; Rajatanavin R
    J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
    Marcocci C; Golia F; Vignali E; Pinchera A
    J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.
    Stall GM; Harris S; Sokoll LJ; Dawson-Hughes B
    Ann Intern Med; 1990 Aug; 113(4):265-9. PubMed ID: 2375563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
    Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroxine suppressive therapy decreases bone mineral density in post-menopausal women.
    Kung AW; Lorentz T; Tam SC
    Clin Endocrinol (Oxf); 1993 Nov; 39(5):535-40. PubMed ID: 8252741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
    Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
    Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopaenia in post-menopausal women.
    Lehmke J; Bogner U; Felsenberg D; Peters H; Schleusener H
    Clin Endocrinol (Oxf); 1992 May; 36(5):511-7. PubMed ID: 1617803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women.
    Paul TL; Kerrigan J; Kelly AM; Braverman LE; Baran DT
    JAMA; 1988 Jun; 259(21):3137-41. PubMed ID: 3367489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
    De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
    Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
    Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
    J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
    Appetecchia M
    Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a past history of thyrotoxicosis.
    Franklyn JA; Betteridge J; Holder R; Sheppard MC
    Thyroid; 1995 Oct; 5(5):359-63. PubMed ID: 8563472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density and metabolism in children treated with L-thyroxine.
    Tümer L; Hasanoğlu A; Cinaz P; Bideci A
    J Pediatr Endocrinol Metab; 1999; 12(4):519-23. PubMed ID: 10417967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
    Kung AW; Yeung SS
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low normal TSH levels are associated with low bone mineral density in healthy postmenopausal women.
    Kim DJ; Khang YH; Koh JM; Shong YK; Kim GS
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):86-90. PubMed ID: 16402934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mass after long-term euthyroidism in former hyperthyroid women treated with (131)I influence of menopausal status.
    Serraclara A; Jódar E; Sarabia F; Hawkins F
    J Clin Densitom; 2001; 4(3):249-55. PubMed ID: 11740067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of long-term thyroxine on bone mineral density and serum cholesterol.
    Fowler PB; McIvor J; Sykes L; Macrae KD
    J R Coll Physicians Lond; 1996; 30(6):527-32. PubMed ID: 8961207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.